Pharmacokinetics and safety of ofloxacin in children with drug-resistant tuberculosis

Anthony J. Garcia-Prats, Heather R. Draper, Stephanie Thee, Kelly Elise Dooley, Helen M. McIlleron, James A. Seddon, Lubbe Wiesner, Sandra Castel, H. Simon Schaaf, Anneke C. Hesseling

Research output: Contribution to journalArticle

Abstract

Ofloxacin is widely used for the treatment of multidrug-resistant tuberculosis (MDR-TB). Data on its pharmacokinetics and safety in children are limited. It is not known whether the current internationally recommended pediatric dosage of 15 to 20 mg/kg of body weight achieves exposures reached in adults with tuberculosis after a standard 800-mg dose (adult median area under the concentration-time curve from 0 to 24 h [AUC0-24], 103 μg · h/ml). We assessed the pharmacokinetics and safety of ofloxacin in children max), AUC0-8, and half-life were 8.97 μg/ml (2.47 to 14.4), 44.2 μg · h/ml (12.1 to 75.8), and 3.49 h (1.89 to 6.95), respectively. The mean AUC0-24, estimated in 72 participants, was 66.7 μg · h/ml (range, 18.8 to 120.7). In multivariable analysis, AUC0-24 was increased by 1.46 μg · h/ml for each 1-kg increase in body weight (95% confidence interval [CI], 0.44 to 2.47; P=0.006); no other assessed variable contributed to the model. No grade 3 or 4 events at least possibly attributed to ofloxacin were observed. Ofloxacin was safe and well tolerated in children with MDR-TB, but exposures were well below reported adult values, suggesting that dosage modification may be required to optimize MDR-TB treatment regimens in children.

Original languageEnglish (US)
Pages (from-to)6073-6079
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume59
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Multidrug-Resistant Tuberculosis
Ofloxacin
Pharmacokinetics
Safety
Body Weight
Half-Life
Tuberculosis
Confidence Intervals
Pediatrics
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Garcia-Prats, A. J., Draper, H. R., Thee, S., Dooley, K. E., McIlleron, H. M., Seddon, J. A., ... Hesseling, A. C. (2015). Pharmacokinetics and safety of ofloxacin in children with drug-resistant tuberculosis. Antimicrobial Agents and Chemotherapy, 59(10), 6073-6079. https://doi.org/10.1128/AAC.01404-15

Pharmacokinetics and safety of ofloxacin in children with drug-resistant tuberculosis. / Garcia-Prats, Anthony J.; Draper, Heather R.; Thee, Stephanie; Dooley, Kelly Elise; McIlleron, Helen M.; Seddon, James A.; Wiesner, Lubbe; Castel, Sandra; Schaaf, H. Simon; Hesseling, Anneke C.

In: Antimicrobial Agents and Chemotherapy, Vol. 59, No. 10, 01.10.2015, p. 6073-6079.

Research output: Contribution to journalArticle

Garcia-Prats, AJ, Draper, HR, Thee, S, Dooley, KE, McIlleron, HM, Seddon, JA, Wiesner, L, Castel, S, Schaaf, HS & Hesseling, AC 2015, 'Pharmacokinetics and safety of ofloxacin in children with drug-resistant tuberculosis', Antimicrobial Agents and Chemotherapy, vol. 59, no. 10, pp. 6073-6079. https://doi.org/10.1128/AAC.01404-15
Garcia-Prats, Anthony J. ; Draper, Heather R. ; Thee, Stephanie ; Dooley, Kelly Elise ; McIlleron, Helen M. ; Seddon, James A. ; Wiesner, Lubbe ; Castel, Sandra ; Schaaf, H. Simon ; Hesseling, Anneke C. / Pharmacokinetics and safety of ofloxacin in children with drug-resistant tuberculosis. In: Antimicrobial Agents and Chemotherapy. 2015 ; Vol. 59, No. 10. pp. 6073-6079.
@article{0deda8221ed342ef8db33981c881fc8e,
title = "Pharmacokinetics and safety of ofloxacin in children with drug-resistant tuberculosis",
abstract = "Ofloxacin is widely used for the treatment of multidrug-resistant tuberculosis (MDR-TB). Data on its pharmacokinetics and safety in children are limited. It is not known whether the current internationally recommended pediatric dosage of 15 to 20 mg/kg of body weight achieves exposures reached in adults with tuberculosis after a standard 800-mg dose (adult median area under the concentration-time curve from 0 to 24 h [AUC0-24], 103 μg · h/ml). We assessed the pharmacokinetics and safety of ofloxacin in children max), AUC0-8, and half-life were 8.97 μg/ml (2.47 to 14.4), 44.2 μg · h/ml (12.1 to 75.8), and 3.49 h (1.89 to 6.95), respectively. The mean AUC0-24, estimated in 72 participants, was 66.7 μg · h/ml (range, 18.8 to 120.7). In multivariable analysis, AUC0-24 was increased by 1.46 μg · h/ml for each 1-kg increase in body weight (95{\%} confidence interval [CI], 0.44 to 2.47; P=0.006); no other assessed variable contributed to the model. No grade 3 or 4 events at least possibly attributed to ofloxacin were observed. Ofloxacin was safe and well tolerated in children with MDR-TB, but exposures were well below reported adult values, suggesting that dosage modification may be required to optimize MDR-TB treatment regimens in children.",
author = "Garcia-Prats, {Anthony J.} and Draper, {Heather R.} and Stephanie Thee and Dooley, {Kelly Elise} and McIlleron, {Helen M.} and Seddon, {James A.} and Lubbe Wiesner and Sandra Castel and Schaaf, {H. Simon} and Hesseling, {Anneke C.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1128/AAC.01404-15",
language = "English (US)",
volume = "59",
pages = "6073--6079",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "10",

}

TY - JOUR

T1 - Pharmacokinetics and safety of ofloxacin in children with drug-resistant tuberculosis

AU - Garcia-Prats, Anthony J.

AU - Draper, Heather R.

AU - Thee, Stephanie

AU - Dooley, Kelly Elise

AU - McIlleron, Helen M.

AU - Seddon, James A.

AU - Wiesner, Lubbe

AU - Castel, Sandra

AU - Schaaf, H. Simon

AU - Hesseling, Anneke C.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Ofloxacin is widely used for the treatment of multidrug-resistant tuberculosis (MDR-TB). Data on its pharmacokinetics and safety in children are limited. It is not known whether the current internationally recommended pediatric dosage of 15 to 20 mg/kg of body weight achieves exposures reached in adults with tuberculosis after a standard 800-mg dose (adult median area under the concentration-time curve from 0 to 24 h [AUC0-24], 103 μg · h/ml). We assessed the pharmacokinetics and safety of ofloxacin in children max), AUC0-8, and half-life were 8.97 μg/ml (2.47 to 14.4), 44.2 μg · h/ml (12.1 to 75.8), and 3.49 h (1.89 to 6.95), respectively. The mean AUC0-24, estimated in 72 participants, was 66.7 μg · h/ml (range, 18.8 to 120.7). In multivariable analysis, AUC0-24 was increased by 1.46 μg · h/ml for each 1-kg increase in body weight (95% confidence interval [CI], 0.44 to 2.47; P=0.006); no other assessed variable contributed to the model. No grade 3 or 4 events at least possibly attributed to ofloxacin were observed. Ofloxacin was safe and well tolerated in children with MDR-TB, but exposures were well below reported adult values, suggesting that dosage modification may be required to optimize MDR-TB treatment regimens in children.

AB - Ofloxacin is widely used for the treatment of multidrug-resistant tuberculosis (MDR-TB). Data on its pharmacokinetics and safety in children are limited. It is not known whether the current internationally recommended pediatric dosage of 15 to 20 mg/kg of body weight achieves exposures reached in adults with tuberculosis after a standard 800-mg dose (adult median area under the concentration-time curve from 0 to 24 h [AUC0-24], 103 μg · h/ml). We assessed the pharmacokinetics and safety of ofloxacin in children max), AUC0-8, and half-life were 8.97 μg/ml (2.47 to 14.4), 44.2 μg · h/ml (12.1 to 75.8), and 3.49 h (1.89 to 6.95), respectively. The mean AUC0-24, estimated in 72 participants, was 66.7 μg · h/ml (range, 18.8 to 120.7). In multivariable analysis, AUC0-24 was increased by 1.46 μg · h/ml for each 1-kg increase in body weight (95% confidence interval [CI], 0.44 to 2.47; P=0.006); no other assessed variable contributed to the model. No grade 3 or 4 events at least possibly attributed to ofloxacin were observed. Ofloxacin was safe and well tolerated in children with MDR-TB, but exposures were well below reported adult values, suggesting that dosage modification may be required to optimize MDR-TB treatment regimens in children.

UR - http://www.scopus.com/inward/record.url?scp=84942900655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942900655&partnerID=8YFLogxK

U2 - 10.1128/AAC.01404-15

DO - 10.1128/AAC.01404-15

M3 - Article

VL - 59

SP - 6073

EP - 6079

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 10

ER -